Navigation Links
PrimeraDx Appoints Leroy Hood to its Scientific Advisory Board

MANSFIELD, Mass., Dec. 6, 2011 /PRNewswire/ -- PrimeraDx today announced that Leroy Hood, MD, PhD, a world recognized leader in the molecular device industry, has been appointed to its Scientific Advisory Board. 

"High multiplex qPCR diagnostics is a key step in bringing personalized medicine to the clinic," commented Dr. Hood.  "I am delighted to help PrimeraDx take the step from an innovative next generation qPCR platform to a robust molecular diagnostics solution."

"Lee brings a breadth of knowledge in the molecular device industry that no one else has.  With Lee's scientific vision we will move forward with our goal of transforming molecular diagnostic medicine and improving patient care," said President and CEO Matthew McManus.

Dr. Hood has established a systems approach to understanding the complexity of biology and medicine.  He has played a pivotal role in the DNA sequencing industry and his innovations were essential for the sequencing of the human genome.  Dr. Hood has been instrumental in the founding of numerous research and commercial enterprises, including Applied Biosystems, Amgen and the Institute for System Biology, where he currently holds the position of President.  He has won several awards and accolades, including; the 2003 AMP award for excellence in Molecular Diagnostics, the Academy of Engineering's Russ Prize, the Lasker Award and the Kyoto Prize.  Dr. Hood has more than 700 peer reviewed articles and is a member of the National Academy of Sciences, the National Academy of Engineering and the Institute of Medicine.

About PrimeraDx

PrimeraDx is a molecular diagnostics company that has developed, and is commercializing, a novel, game-changing clinical platform which combines PCR with capillary electrophoresis.  The result of combining these two well-known technologies into a bench-top instrument is the ability to deliver highly multiplexed and quantitative answers to the clinic.  The company is pursuing a two pronged strategy to sell the system in an Open Platform Mode to clinical labs and to collaborate with pharmaceutical companies to develop high-value companion and enabling diagnostic products.  Users can easily design very complex multi-modal assays that test for disparate target types, like SNPs, expression biomarkers, microRNAs and fusion genes.  PrimeraDx's technology represents the next generation of quantitative PCR.  The Company is backed by a strong group of experienced venture-capital investors, including Abingworth, InterWest Partners, CHL Medical Partners, and Malaysia Technology Development Corporation.  The Company's website is: or

CONTACT: Andrew Bond, +1-508-618-2752,

SOURCE PrimeraDx
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PrimeraDx Appoints David Heffelfinger as VP of Engineering and Systems Development
2. PrimeraDx Launches the Only System Capable of Simultaneous Quantification of mRNA, microRNA and DNA
3. Ulthera Appoints Greg Waller as Chief Financial Officer
4. Tengion Appoints John L. Miclot President and Chief Executive Officer
5. Remedi SeniorCare® Appoints Corey Gauff SVP of Sales and Account Management
6. Ultragenyx Appoints Tom Kassberg as Chief Business Officer and Announces Management Team
7. CVS Caremark Appoints Kevin Murphy President of Accordant Business
8. Valeant Pharmaceuticals Appoints Howard B. Schiller as Chief Financial Officer
9. Adeona Appoints Jeff Lucero Riley as Independent Chairman
10. Champions Oncology, Inc. Appoints Executive Vice President and Chief Financial Officer to Management Team and Corporate Office Relocation
11. InterMune Appoints Angus C. Russell to Board of Directors
Post Your Comments:
(Date:10/13/2015)... 13, 2015  Yesterday Congresswoman Renee Ellmers ... manufacturing site located in Holly Springs, NC ... produced Flucelvax ® (Influenza Vaccine) using cell-culture technology, a ... start-up and is not reliant on chicken eggs. 1,2 ... influenza vaccines business of Novartis AG in the US, ...
(Date:10/12/2015)... -- Given the intricacy of the anatomy and ... an ophthalmic drug effectively to a specific ocular site. Several ... delivery. These include dilution of a drug by tears, clearance ... drug permeation issues with respect to the cornea, sclera and ... is lost due to the aforementioned barriers. --> ...
(Date:10/12/2015)... and CRANBURY, N.J. , Oct. ... LLP announces that a securities fraud class ... for the District of New Jersey.  The complaint alleges ... FOLD) violated the Securities Exchange Act of 1934 between ... materially false and misleading statements about Amicus Therapeutics, business ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 2015 , ... NavaFit Inc. today announced the launch of its NavaFit app ... in local fitness & sporting events, and stay motivated. Users can download ... drive us to get more serious about fitness and wellness, individuals are constantly looking ...
(Date:10/13/2015)... ... October 13, 2015 , ... Altec ... their Title Sponsorship of Synergy 2015. The annual WennSoft KEY2ACT user conference will ... Ranch and will unite customers, partners, WennSoft team members and sponsors to facilitate ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... telemedicine programs in communities throughout Georgia, along with affiliate organizations, Alabama Partnership for ... their regional telehealth summits for Fall 2015. , Each of the three ...
(Date:10/13/2015)... ... October 13, 2015 , ... Local Gold’s Gym franchise owner, Bryce ... on August 26. Berry, who owns and operates Gold's Gym Cheyenne in ... Gold’s Gyms in the United States. A brand leader in global fitness, Gold’s Gyms ...
(Date:10/13/2015)... ... October 13, 2015 , ... With Fall weather approaching and ... for this month’s Facebook Hair Styler Contest. , Enter to win! , How to ... What Is Your Favorite Hair Style? , 3. Follow us on Instagram @thebeautyplace ...
Breaking Medicine News(10 mins):